Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORB | Q92753 | 13/20 | 0.42 |
| ▸ | RORC | P51449 | 6/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706766 | 0.90 | RORB (0.43) | RORBRORCGRM2TACR1CDC7 | |
| SCHEMBL4708632 | 0.87 | RORB (0.42) | RORBRORCGRM2TACR1CDC7 | |
| SCHEMBL4708296 | 0.86 | RORB (0.41) | RORBRORCGRM2TACR1IDH1 | |
| SCHEMBL4707765 | 0.86 | RORB (0.40) | RORBRORCGRM2TACR1IDH1 | |
| SCHEMBL4705482 | 0.82 | RORB (0.41) | RORBRORCGRM2TACR1IDH1 | |
| SCHEMBL4705450 | 0.82 | RORB (0.42) | RORBRORCGRM2CDC7GABRA2 | |
| SCHEMBL6389497 | 0.82 | IDH1 (0.42) | RORBRORCCDC7IDH1GABRA2 | |
| SCHEMBL4705403 | 0.82 | RORB (0.41) | RORBRORCGRM2CDC7IDH1 | |
| SCHEMBL4707133 | 0.82 | RORB (0.40) | RORBRORCGRM2TACR1IDH1 | |
| SCHEMBL4707207 | 0.81 | RORB (0.40) | RORBRORCGRM2TACR1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY COMPANY (US) | 2005-10-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | TACR1, TACR2, BDKRB1 | RORB 2614/4885RORC 2723/4885GRM2 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.